@article{070db4cbc6714e97beb9b62edbb50ee3,
title = "Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer",
abstract = "Systemic inflammation is believed to contribute to the distant recurrence of breast cancer. We evaluated serum samples obtained at diagnosis from 249 case:control pairs with stage II-III Her2-negative breast cancer with or without subsequent distant recurrence. Conditional logistic regression analysis, with models fit via maximum likelihood, were used to estimate hazard ratios (HRs) and test for associations of cytokines with distant recurrence risk. The only biomarker associated with a significantly increased distant recurrence risk when adjusted for multiple testing was the proinflammatory cytokine IL-6 (HR 1.37, 95% confidence intervals [CI] 1.15, 1.65, p = 0.0006). This prospective-retrospective study provides evidence indicating that higher levels of the cytokine IL-6 at diagnosis are associated with a significantly higher distant recurrence risk.",
author = "Sparano, {Joseph A.} and Anne O{\textquoteright}Neill and Noah Graham and Northfelt, {Donald W.} and Dang, {Chau T.} and Wolff, {Antonio C.} and Sledge, {George W.} and Miller, {Kathy D.}",
note = "Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O{\textquoteright}Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: U10CA180820, U10CA180794, U10CA180821, UG1CA189859, UG1CA232760, UG1CA233290, and UG1CA233196. Also supported by the Breast Cancer Research Foundation and Susan G. Komen Foundation (J.A.S., MD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. government. Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O?Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: U10CA180820, U10CA180794, U10CA180821, UG1CA189859, UG1CA232760, UG1CA233290, and UG1CA233196. Also supported by the Breast Cancer Research Foundation and Susan G. Komen Foundation (J.A.S., MD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. government. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1038/s41523-021-00376-9",
language = "English (US)",
volume = "8",
journal = "npj Breast Cancer",
issn = "2374-4677",
publisher = "Nature Publishing Group",
number = "1",
}